OncoAlert

The OncoAlert ??Newsletter NOW OUT September November 1-7, 2024 REGISTER AT https://Oncoalert360.com OR https://lnkd.in/d7QR5f-6 Discussing: ?Targeted Tx, Novel ab, and io in #NSCLC ???? ?role of RT in mgt of male breast cancer?? Icro Meattini Giuseppe Curigliano Elisabetta Bonzano ?SERENA-2 in #BreastCancer Mafalda Oliveira Erika Hamilton, MD ?Dietary quality ??& chemo induced peripheral neuropathy?? in #ColonCancer American Cancer Society Journals ? NRG Oncology Intl.??Consensus Contouring #PancreaticCancer Nina Sanford ?Impact of postprogression tx on OS in #RCC Pavlos Msaouel, MD, PhD ?regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic #CRC ?Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer Kohei Shitara ???? ?Onvansertib in combo w/Chemotherapy and Bevacizumab in 2L- Tx of KRAS-Mutant Metastatic #ColorectalCancer Matteo Lambertini Yüksel üRüN Petros Grivas Benedikt Westphalen Westphalen Janice Cowden Cathy Eng Sharlene Gill MD, MPH, MBA, FASCO, FRCP(C) Allison Rosen, MS Pashtoon Kasi #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps--Maléa Biagio Ricciuti Emre Yekeduz Hidehito Horinouchi Fadi Haddad José Fernando Prado Moura Elisa Agostinetto Elisabetta Bonzano Eric Singhi Bárbara Mel?o Dr. Joseph McCollom DO Fabio Martinelli Luca Arecco Niklas Klümper

An amazing group pf Colleagues, Proud of all of you and specially OUR dear friend Lucia Del Mastro!!!

Results suggest that PSMA PET/CT and mpMRI are complementary, with PSMA PET/CT potentially enhancing detection of smaller, clinically significant tumors in #ProstateCancer

Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study Out on JCO This study aimed to evaluate the nodal burden and outcomes in breast cancer patients with isolated tumor cells (ITCs) in sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC), focusing on those treated with or without axillary lymph node dissection (ALND). Analyzing data from 583 patients across 62 centers, the study found that additional positive lymph nodes were identified in 30% of patients undergoing ALND, but only 5% had macrometastases. The 3-year rates of axillary and invasive recurrence were low (2% and 11%, respectively), with no significant differences between patients treated with or without ALND. These findings suggest that routine ALND may not be necessary in all patients with ypN0(i+), as the nodal burden and recurrence rates were low. https://lnkd.in/dtYPP5WB Giacomo Montagna MD MPH FSSO Massimo Ferrucci suleyman bademler Hakan Balbaloglu ?Prof. Dr. Maggie Banys-Paluchowski John Benson ?Nuran Senel Bese Judy Boughey ?Marissa Boyle Maite Goldschmidt ?Martin Heidinger Guldeniz Karadeniz Cakmak MD, FACS, FEBS Cakmak Susan Kesmodel ?Henry Kuerer, MD,PhD, FACS ?Julie Loesch ?Tracy-Ann Moo ?Tehillah Menes ?Jessica Michelle Pastoriza ?Perhavec Andra? Natália Polidorio Avina Rami Jai Min Ryu ?Alexander Schulz (Ph.D.) Varadan Sevilimedu Annemiek van Hemert HASAN KARANLIK Neslihan Cab?o?lu Marie-Jeanne Vrancken Peeters

Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial Out on Lancet Oncology This randomized, placebo-controlled phase 2 trial investigated the efficacy and safety of combining the PD-1 inhibitor toripalimab with concurrent chemoradiotherapy (CRT) for patients with high-risk locoregionally advanced nasopharyngeal carcinoma (NPC). Conducted at Sun Yat-sen University Cancer Centre, 150 patients were enrolled and randomly assigned to receive either neoadjuvant–adjuvant toripalimab or placebo alongside CRT. After a median follow-up of 37.8 months, the 2-year progression-free survival (PFS) was significantly higher in the toripalimab group (92%) compared to placebo (74%). Although both groups experienced similar rates of adverse events, immune-mediated grade 3 or worse events occurred only in the toripalimab group. These findings suggest that the addition of toripalimab to CRT may offer a promising treatment option for advanced NPC, warranting further phase 3 studies. https://lnkd.in/dhJw5hgB

A warm Congratulations to Dr. Noha Rashad ????Medical Oncologist at Suez University, Faculty of Medicine, Egypt. Recipient of an OncoAlert ??CATALYST fellowship supported by Roche. Her Project is: "GI Characterize" In her words: The "GI Characterize" initiative aims to focus on understudied gastrointestinal cancers in Egypt. Multiple questions related to the etiology, clinicopathological features and prognosis of patients with GIT malignancies in Egypt needs to be addressed. A series of multicentric cohort studies covering pancreatic cancer, gastric and GEJ cancer, biliary cancer and neuroendocrine neoplasms will be conducted to address some of these questions and pave the way for further research. Kudos to her and all other Catalyst Fellows Pashtoon Kasi Cathy Eng Sharlene Gill MD, MPH, MBA, FASCO, FRCP(C) Allison Rosen, MS Stacy Hurt ?? Kohei Shitara Benedikt Westphalen Dra. María Natalia Gandur Quiroga Elisa Agostinetto Elisabetta Bonzano Dr. Joseph McCollom DO José Fernando Prado Moura Biagio Ricciuti Jo?o Mouta

The OncoAlert ??RoundUp Covering September November 1-7, 2024 REGISTER AT https://Oncoalert360.com OR https://lnkd.in/d7QR5f-6 https://lnkd.in/d5UdKwbs Mafalda Oliveira Carmen Criscitiello Bruno Meduri Phuong Ly-Gallagher Salvatore La Rosa Salvatore La Rosa Matthew Campbell Walter Stadler Stephanie Berg Antonio Giordano Castalia Fernandez Pascual Nicole Stout DPT, CLT-LANA, FAPTA Kristen Sullivan Matteo Lambertini Yüksel üRüN Petros Grivas Cathy Eng #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps--Maléa Biagio Ricciuti Emre Yekeduz Hidehito Horinouchi José Fernando Prado Moura Elisa Agostinetto Eric Singhi Bárbara Mel?o Dr. Joseph McCollom DO Fabio Martinelli Luca Arecco

Glad to be practicing in an era of #immunotherapy. ????REGO?IPI?NIVO was potentially CURATIVE in microsatellite stable tumors?????? …6 patients had ongoing benefit, including 3 who remain cancer-free >18 months after treatment… Magic word???? #CURE #CRCSM OncoAlert City of Hope

In case you missed #ESMO24 and would like some highlights or wrap up on trials presented like PEACE3, NIAGARA & more Check out our Coverage at our OncoAlert ESMO24 Playlist in our YouTube Channel, Fast, accurate Oncology information, by some top colleagues in Oncology. OncoAlert...For Colleagues...By Colleagues ?? Gil Morgan Bárbara Mel?o Dra. María Natalia Gandur Quiroga Leonor Vasconcelos de Matos Luca Arecco Eva Schumacher-Wulf Hidehito Horinouchi Alessandro Di Federico

During #APCCC24 ,the question came up: What are the treatment preferences for patients with high-risk localized or locally advanced #ProstateCancer and (N0 M0) negative nodal and metastatic status on next-generation imaging, the panel responded in the following way with NO ?? consensus reached